Roivant Sciences Ltd. - Common Shares (ROIV) closed at $35.89 on November 2, 2026, down 2.8% from the previous close, on volume of 5,393,063 shares (30-day average 6,257,889).
Data as of November 2, 2026.
2-Nov-2026
Leerink Partners Remains a Buy on Roivant Sciences (ROIV)
TipRanks (Mon, 2-Nov 11:43 AM ET)
Globe Newswire (Thu, 29-Oct 9:00 AM ET)
Roivant jumps after Phase 3 NIU data show brepocitinib pushed median time-to-failure past 48 weeks
Market Chameleon (Wed, 21-Oct 6:47 AM ET)
Market Chameleon (Wed, 21-Oct 3:44 AM ET)
Globe Newswire (Wed, 21-Oct 7:00 AM ET)
Globe Newswire (Wed, 21-Oct 7:00 AM ET)
Globe Newswire (Wed, 21-Oct 7:00 AM ET)
Globe Newswire (Wed, 23-Sep 7:00 AM ET)
Globe Newswire (Wed, 23-Sep 7:00 AM ET)
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Roivant Sciences Ltd. - Common Shares trades on the NASDAQ stock market under the symbol ROIV.
As of November 2, 2026, ROIV stock price declined to $35.89 with 5,393,063 million shares trading.
ROIV has a beta of 0.56, meaning it tends to be less sensitive to market movements. ROIV has a correlation of 0.03 to the broad based SPY ETF.
ROIV has a market cap of $25.93 billion. This is considered a Large Cap stock.
Last quarter Roivant Sciences Ltd. - Common Shares reported $1 million in Revenue and -$.34 earnings per share. This fell short of revenue expectation by $-903,840 and exceeded earnings estimates by $.03.
In the last 3 years, ROIV traded as high as $42.50 and as low as $8.29.
The top ETF exchange traded funds that ROIV belongs to (by Net Assets): IJH, VTI, VB, XMMO, VBK.
ROIV has outperformed the market in the last year with a price return of +83.3% while the SPY ETF gained +11.7%. ROIV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +4.0% and +7.0%, respectively, while the SPY returned +1.7% and -1.5%, respectively.
ROIV support price is $36.02 and resistance is $37.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ROIV shares will trade within this expected range on the day.
